At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Umbrella Study in Relapsed/Refractory Peripheral T-cell Lymphoma Guided by Molecular Subtypes
In Brief
A Phase 2 clinical trial evaluating Azacitidine Injection, Dasatinib, and 5 other interventions for Peripheral T Cell Lymphoma. Targeting 116 participants across 1 site.
Detailed Summary
This is a multicenter, prospective, open-label, interventional umbrella study to evaluate the efficacy and safety of targeted therapies guided by molecular subtypes in patients with relasped or refractory peripheral T-cell lymphoma.
Study Details
Timeline
Interventions
Azacitidine Injection，SC and Dasatinib PO will be administered in T1 subtypes
Azacitidine Injection，SC and Dasatinib PO will be administered in T1 subtypes
Azacitidine Injection，SC and Linperlisib PO will be administered in T2 subtypes
Tucidinostat PO and SHR2554 PO will be administered in T3.1 subtypes
Tucidinostat PO and SHR2554 PO will be administered in T3.1 subtypes
Camrelizumab and Apatinib will be administered in T3.2 subtypes
Camrelizumab and Apatinib will be administered in T3.2 subtypes